Reference number : 236-2013-2014-Q4-00463, amendment number : , agreement type : G, recipient legal name : TSANTRIZOS, Youla S, recipient country : CA, recipient province : QC, recipient city : Montreal, recipient postal code : H3A 2T5, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 160000.0, agreement start date : 2014-04-01, agreement end date : 2015-03-31, description english : Benchmark proprietary pyridine- and thienopyrimidine-based bisphosphonates against the standard of care drug Zometa® in the treatment of multiple myeloma, description french : Benchmark proprietary pyridine- and thienopyrimidine-based bisphosphonates against the standard of care drug Zometa® in the treatment of multiple myeloma, expected results english : nan, expected results french : nan, additional information english : nan, additional information french : nan, owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada